
Diabetic Peripheral Neuropathy- Pipeline Insight, 2025
Description
DelveInsight’s, “Diabetic Peripheral Neuropathy- Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Diabetic Peripheral Neuropathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Diabetic Peripheral Neuropathy: Overview
Diabetic peripheral neuropathy (DPN) is a common and debilitating complication of diabetes, affecting up to 50% of patients with both type 1 and type 2 diabetes. DPN primarily results from prolonged hyperglycemia, which causes progressive nerve damage, starting with the distal sensory and autonomic fibers and advancing proximally. This gradual degeneration of the peripheral nervous system results in a wide range of sensory, motor, and autonomic dysfunctions. Clinically, patients often present with symptoms such as numbness, tingling, burning sensations, aching, or sharp, shooting pains, predominantly in the lower extremities.
Diabetic peripheral neuropathy (DPN) is a severe diabetes complication resulting from prolonged high blood sugar levels, causing nerve damage, particularly in the feet and legs. Common symptoms include:
Numbness, Tingling or ""Pins and Needles, Burning Sensation, Sharp Pain or Cramps, Extreme Sensitivity to Touch, Loss of Balance and Coordination, Muscle Weakness and Digestive and Autonomic Symptoms.
Risk factors for DPN are multifaceted and include advanced age, where aging processes naturally predispose the nervous system to degeneration. Hypertension and dyslipidemia, both common comorbidities in diabetic patients, exacerbate vascular damage and contribute to the reduced blood flow to nerves, furthering their vulnerability to injury. Peripheral vascular disease, often seen in diabetic individuals, similarly restricts adequate blood supply to nerves, leading to ischemic damage. Smoking compounds the risk of neuropathy by promoting vasoconstriction and oxidative stress, while excessive alcohol consumption can cause both direct neurotoxicity and worsen glycemic control.
The pathophysiology of DPN is largely driven by chronic hyperglycemia, which initiates a cascade of biochemical changes, leading to nerve damage. Elevated serum glucose levels result in insulin resistance and dyslipidemia, both of which contribute to significant oxidative stress within the endoplasmic reticulum and mitochondria of peripheral nerve cells. This oxidative stress occurs due to the excessive production of reactive oxygen species (ROS), which overwhelm the cell's antioxidant defense mechanisms. Diabetic peripheral neuropathy (DPN) is diagnosed through several steps, starting with a detailed clinical history and physical examination to assess symptoms and exclude other causes of neuropathy. Key diagnostic methods include neurological assessments such as nerve conduction studies, quantitative sensory testing, and skin biopsies to evaluate nerve damage. Clinical scoring systems like the Michigan Neuropathy Screening Instrument (MNSI) and Neuropathy Disability Score (NDS) help gauge DPN severity. Emerging tools, such as the Vibration Perception Threshold (VPT) and retinal vascular geometry analysis, offer additional ways to detect and monitor DPN.
Managing diabetic peripheral neuropathy (DPN) involves a multi-faceted approach that includes preventive measures, conservative, pharmacological, interventional, and alternative therapies. Preventive strategies focus on glucose control, foot care, and education to avoid complications. Conservative treatments like physical therapy and non-invasive techniques help improve mobility and reduce pain. Pharmacological treatments include gabapentinoids, SNRIs, and topical agents to manage neuropathic pain. Interventional therapies, such as spinal cord stimulation, are used for severe cases. Alternative therapies, including omega-3 supplements and vitamin D, may offer additional benefits in managing symptoms and improving quality of life.
""Diabetic Peripheral Neuropathy- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diabetic Peripheral Neuropathy pipeline landscape is provided which includes the disease overview and Diabetic Peripheral Neuropathy treatment guidelines. The assessment part of the report embraces, in depth Diabetic Peripheral Neuropathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetic Peripheral Neuropathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Diabetic Peripheral Neuropathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Diabetic Peripheral Neuropathy Emerging Drugs
Further product details are provided in the report……..
Diabetic Peripheral Neuropathy: Therapeutic Assessment
This segment of the report provides insights about the different Diabetic Peripheral Neuropathy drugs segregated based on following parameters that define the scope of the report, such as:
Diabetic Peripheral Neuropathy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Diabetic Peripheral Neuropathy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diabetic Peripheral Neuropathy drugs.
Diabetic Peripheral Neuropathy Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Diabetic Peripheral Neuropathy: Overview
Diabetic peripheral neuropathy (DPN) is a common and debilitating complication of diabetes, affecting up to 50% of patients with both type 1 and type 2 diabetes. DPN primarily results from prolonged hyperglycemia, which causes progressive nerve damage, starting with the distal sensory and autonomic fibers and advancing proximally. This gradual degeneration of the peripheral nervous system results in a wide range of sensory, motor, and autonomic dysfunctions. Clinically, patients often present with symptoms such as numbness, tingling, burning sensations, aching, or sharp, shooting pains, predominantly in the lower extremities.
Diabetic peripheral neuropathy (DPN) is a severe diabetes complication resulting from prolonged high blood sugar levels, causing nerve damage, particularly in the feet and legs. Common symptoms include:
Numbness, Tingling or ""Pins and Needles, Burning Sensation, Sharp Pain or Cramps, Extreme Sensitivity to Touch, Loss of Balance and Coordination, Muscle Weakness and Digestive and Autonomic Symptoms.
Risk factors for DPN are multifaceted and include advanced age, where aging processes naturally predispose the nervous system to degeneration. Hypertension and dyslipidemia, both common comorbidities in diabetic patients, exacerbate vascular damage and contribute to the reduced blood flow to nerves, furthering their vulnerability to injury. Peripheral vascular disease, often seen in diabetic individuals, similarly restricts adequate blood supply to nerves, leading to ischemic damage. Smoking compounds the risk of neuropathy by promoting vasoconstriction and oxidative stress, while excessive alcohol consumption can cause both direct neurotoxicity and worsen glycemic control.
The pathophysiology of DPN is largely driven by chronic hyperglycemia, which initiates a cascade of biochemical changes, leading to nerve damage. Elevated serum glucose levels result in insulin resistance and dyslipidemia, both of which contribute to significant oxidative stress within the endoplasmic reticulum and mitochondria of peripheral nerve cells. This oxidative stress occurs due to the excessive production of reactive oxygen species (ROS), which overwhelm the cell's antioxidant defense mechanisms. Diabetic peripheral neuropathy (DPN) is diagnosed through several steps, starting with a detailed clinical history and physical examination to assess symptoms and exclude other causes of neuropathy. Key diagnostic methods include neurological assessments such as nerve conduction studies, quantitative sensory testing, and skin biopsies to evaluate nerve damage. Clinical scoring systems like the Michigan Neuropathy Screening Instrument (MNSI) and Neuropathy Disability Score (NDS) help gauge DPN severity. Emerging tools, such as the Vibration Perception Threshold (VPT) and retinal vascular geometry analysis, offer additional ways to detect and monitor DPN.
Managing diabetic peripheral neuropathy (DPN) involves a multi-faceted approach that includes preventive measures, conservative, pharmacological, interventional, and alternative therapies. Preventive strategies focus on glucose control, foot care, and education to avoid complications. Conservative treatments like physical therapy and non-invasive techniques help improve mobility and reduce pain. Pharmacological treatments include gabapentinoids, SNRIs, and topical agents to manage neuropathic pain. Interventional therapies, such as spinal cord stimulation, are used for severe cases. Alternative therapies, including omega-3 supplements and vitamin D, may offer additional benefits in managing symptoms and improving quality of life.
""Diabetic Peripheral Neuropathy- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diabetic Peripheral Neuropathy pipeline landscape is provided which includes the disease overview and Diabetic Peripheral Neuropathy treatment guidelines. The assessment part of the report embraces, in depth Diabetic Peripheral Neuropathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetic Peripheral Neuropathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Diabetic Peripheral Neuropathy R&D. The therapies under development are focused on novel approaches to treat/improve Diabetic Peripheral Neuropathy.
This segment of the Diabetic Peripheral Neuropathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Diabetic Peripheral Neuropathy Emerging Drugs
- Adezunap: Apurano Pharmaceuticals
- NRD.E1: Novaremed
- TRV045: Trevena
Further product details are provided in the report……..
Diabetic Peripheral Neuropathy: Therapeutic Assessment
This segment of the report provides insights about the different Diabetic Peripheral Neuropathy drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Diabetic Peripheral Neuropathy
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intravenous
- Subcutaneous
- Oral
- Intramuscular
- Molecule Type
- Monoclonal antibody
- Small molecule
- Peptide
- Product Type
Diabetic Peripheral Neuropathy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Diabetic Peripheral Neuropathy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diabetic Peripheral Neuropathy drugs.
Diabetic Peripheral Neuropathy Report Insights
- Diabetic Peripheral Neuropathy Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Diabetic Peripheral Neuropathy drugs?
- How many Diabetic Peripheral Neuropathy drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diabetic Peripheral Neuropathy?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Diabetic Peripheral Neuropathy therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Diabetic Peripheral Neuropathy and their status?
- What are the key designations that have been granted to the emerging drugs?
- Apurano Pharmaceuticals
- Novaremed
- Trevena
- Helixmith
- Applied Therapeutics
- WinSanTor
- Centrexion Therapeutics
- Praetego
- Adezunap
- NRD.E1
- TRV045
- Engensis
- AT-001
- WST-057
- CNTX-6016
- PTG-630
Table of Contents
80 Pages
- Introduction
- Executive Summary
- Diabetic Peripheral Neuropathy: Overview
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Diabetic Peripheral Neuropathy– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Adezunap: Apurano Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- NRD.E1: Novaremed
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- TRV045: Trevena
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Diabetic Peripheral Neuropathy Key Companies
- Diabetic Peripheral Neuropathy Key Products
- Diabetic Peripheral Neuropathy- Unmet Needs
- Diabetic Peripheral Neuropathy- Market Drivers and Barriers
- Diabetic Peripheral Neuropathy- Future Perspectives and Conclusion
- Diabetic Peripheral Neuropathy Analyst Views
- Diabetic Peripheral Neuropathy Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.